Industry Supported Sessions

OPTIMISING PATIENT MANAGEMENT WITH ANTI-GD2 IMMUNOTHERAPY

SYMPOSIUM ORGANIZED AND SPONSORED BY EUSAPharma

This session is not included in main conference CME/CPD credit

07:30-08:45 EDT

Chair: Dr. Giuseppe Barone, UK

07:30 – 07:35 WELCOME AND INTRODUCTIONS

Dr. Giuseppe Barone, UK

07:35 – 07:50 Treatment outcomes with Qarziba as front-line maintenance therapy

Dr. Vassilios Papadakis, Greece

07:50 – 08:05 Enhancing the patient experience: Strategies for managing adverse events

Dr. Giuseppe Barone, UK

08:05 – 08:25 Qarziba in the clinic: Patient case studies discussion

Dr. Giuseppe Barone, UK and Dr. Vassilios Papadakis, Greece

08:25 – 08:45 LIVE Q&A SESSION AND CLOSING

All Faculty

BUILDING BRIDGES TO ENSURE BEST POSSIBLE OUTCOMES FOR ALL PEOPLE WITH ALL

SYMPOSIUM ORGANIZED AND SPONSORED BY SERVIER

This session is not included in main conference CME/CPD credit

09:40-12:00 EDT

Chairs: Dan Douer & Scott Howard, USA

09:40 – 09:45 Welcome to the Building ALL Bridges Symposium & welcome from the Satellite Hub in Italy

Carmelo Rizzari, Italy

09:45 – 09:48 Welcome from the Satellite hubs: Canada

Donna Johnston, Canada

09:48 – 09:51 Welcome from the Satellite hubs: The Netherlands

Gertjan Kaspers, The Netherlands

09:51 – 09:54 Welcome from the Satellite hubs: slovakia

Alexandra Kolenova, Slovakia

09:54 – 09:59 Introduction to the Symposium objectives

Dan Douer, USA

09:59 – 10:14 What are the biological difference between ALL in children and adults?

Stephen Hunger, USA

10:14 – 10:24 Main steps in the history of the development of ALL treatment concept (Pediatric)

Carmelo Rizzari, Italy

10:24– 10:34 Main steps in the history of the development of ALL treatment concept (ADULTS)

Dan Douer, USA

10:34 – 10:54 Differences in treatment toxicities between ALL children and adults. Is there a cutoff age?

Kjeld Schmiegelow, Sweden

10:54 – 11:09 Immunotherapy and CAR-T cells: comparing experiences in children

Andrea Biondi, Italy

11:09 – 11:24 Immunotherapy and CAR-T cells: comparing experiences in adults

Nicolas Boissel, France

11:24 – 11:44 Best available treatment for AYA ALL patients

Rob Pieters, The Netherlands

11:44 – 11:54 Questions and wrap up of the first session

Scott Howard, USA

11:54 – 12:00 Call to Action: Building ALL Bridges

Carmelo Rizzari, Italy and Dan Douer, USA

Let us be practical about collaboration. Experience shared

SYMPOSIUM ORGANIZED AND SPONSORED BY SERVIER

This session is not included in main conference CME/CPD credit

12:20-13:45 EDT

12:20 – 12:40 Age-adaption in the newly designed ALLTogether protocol: PI, Mats Heyman talks about reasons for adaptation and how these adaptations will be evaluated

Mats Heyman, Sweden

12:40 – 13:00 Practicalities of working together. Experience from Italy

Andrea Biondi & Renato Bassan, Italy

13:00 – 13:20 Practicalities of working together. Experience from the netherlands

Rob Pieters & Lotte v/d Wagen, the Netherlands

13:20 – 13:30 Practicalities of working together. Experience from france

Nicolas Boissel, France

13:30 – 13:40 Practicalities of working together. Experience from slovakia

Alexandra Kolenova, Slovakia

13:40 – 13:45 next steps

Scott Howard, USA

ON THE HORIZON: IMMUNOTHERAPY STRATEGIES FOR RELAPSED/REFRACTORY HIGH-RISK NEUROBLASTOMA

SYMPOSIUM ORGANIZED AND SPONSORED BY Ology Medical Education 

* This session is not included in main conference CME/CPD credit

*Independent CME-accredited satellite symposium

*Jointly provided by Postgraduate Institute for Medicine and Ology Medical Education and supported by an independent educational grant from Y-mAbs Therapeutics, Inc.

12:00-13:30 EDT

Chair: Susan Cohn, USA

12:00 – 12:10: WELCOME AND INTRODUCTION

Susan Cohn, USA

12:10 – 12:35: Unmet needs in R/R high-risk neuroblastoma: rising to the challenge

Susan Cohn, USA

12:35 – 13:00: Targeted antibody-based immunotherapy approaches in the R/R setting: evidence and perspectives

Daniel Morgenstern, Canada

13:00 – 13:25: Optimizing clinical management and treatment outcomes: a multidisciplinary approach

Jaume Mora, Spain

13:25 – 14:00: LIVE SUMMARY SESSION

All Faculty, the discussion will continue as Meet the Experts Q&A in the chat room until 14:00

EPIGENETIC MODIFIERS IN PEDIATRIC ONCOLOGY

SYMPOSIUM ORGANIZED AND SPONSORED BY Bristol-Myers Squibb 

This session is not included in main conference CME/CPD credit

07:30-08:30 EDT

Chair: Eric Bouffet, Canada

07:30 – 07:35 OPENING REMARKS

Eric Bouffet, Canada

07:35 – 07:50 HDAC INHIBITION

Kimberly Stegmaier, USA

07:50 – 08:05 BET INHIBITION

Franck Bourdeaut, France

08:05 – 08:20 MENIN INHIBITION

Michel Zwaan, Netherlands

08:20 – 08:30 LIVE Q&A SESSION

All Faculty

IMPROVING CHILDREN CARE WITH TEMOZOLOMIDE ORAL SUSPENSION

PRODUCT THEATRE SESSION ORGANIZED AND SPONSORED BY Orphelia Pharma

This session is not included in main conference CME/CPD credit

09:15-09:35 EDT

09:15 – 09:22 Temozolomide in treatment of relapsed or refractory pediatric tumors

Lucas Moreno, Spain

09:22 – 09:29 Efficacy and safety of temozolomide-based regimen for relapsed or refractory neuroblastoma

Dominique Valteau-Couanet, France

09:29 – 09:33 Development of Kimozo: a ready-to-use and taste masked oral suspension of temozolomide

Caroline Lemarchand, France